Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 12 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Hormones Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1996 2022

Research Output 1985 2017

  • 12489 Citations
  • 42 h-Index
  • 110 Article
  • 14 Review article
  • 5 Comment/debate

Academic cancer center phase i program development

Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P. Apr 1 2017 In : Oncologist. 22, 4, p. 369-374 6 p.

Research output: Research - peer-reviewComment/debate

Program Development
Neoplasms
Research
Research Personnel
Clinical Trials
1 Citations

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, I. B., Smith, D. C., Berger, R., Kurzrock, R., Vogelzang, N. J., Sella, A., Wheler, J., Lee, Y., Foster, P. G., Weitzman, R. & Buckanovich, R. J. Sep 1 2017 In : European Journal of Cancer. 83, p. 229-236 8 p.

Research output: Research - peer-reviewArticle

Carcinoma
cabozantinib
Disease-Free Survival
Neoplasms
Random Allocation
11 Citations

Integrative clinical genomics of metastatic cancer

Robinson, D. R. , Wu, Y. M. , Lonigro, R. J. , Vats, P. , Cobain, E. , Everett, J. , Cao, X. , Rabban, E. , Kumar-Sinha, C. , Raymond, V. , Schuetze, S. , Alva, A. , Siddiqui, J. , Chugh, R. , Worden, F. , Zalupski, M. M. , Innis, J. , Mody, R. J. , Tomlins, S. A. , Lucas, D. & 13 others Baker, L. H., Ramnath, N., Schott, A. F., Hayes, D. F., Vijai, J., Offit, K., Stoffel, E. M., Roberts, J. S., Smith, D. C., Kunju, L. P., Talpaz, M., Cieślik, M. & Chinnaiyan, A. M. Aug 17 2017 In : Nature. 548, 7667, p. 297-303 7 p.

Research output: Research - peer-reviewArticle

Genomics
Neoplasms
Exome
RNA Sequence Analysis
Tumor Microenvironment
14 Citations

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A. 2017 In : Cancer Discovery. 7, 6, p. 620-629 10 p.

Research output: Research - peer-reviewArticle

Mutation
Neoplasms
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Small Cell Lung Carcinoma

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Schöffski, P., Gordon, M., Smith, D. C., Kurzrock, R., Daud, A., Vogelzang, N. J., Lee, Y., Scheffold, C. & Shapiro, G. I. Nov 1 2017 In : European Journal of Cancer. 86, p. 296-304 9 p.

Research output: Research - peer-reviewArticle

Neoplasms
cabozantinib
Castration
Ovarian Neoplasms
Prostatic Neoplasms